Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

Official Title

A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Orally Administered GLPG1690 in Subjects With Systemic Sclerosis

Keywords

Systemic Sclerosis Scleroderma, Systemic Scleroderma, Diffuse Sclerosis GLPG1690

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female subjects who completed the 24-week treatment period of Study GLPG1690-CL-204 and who according to the investigator's judgment may benefit from long-term treatment with GLPG1690.

You CAN'T join if...

  • Any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Locations

  • UCLA Rheumatology
    Los Angeles California 90095 United States
  • Pacific Arthritis Care Center
    Los Angeles California 90045 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Galapagos NV
ID
NCT03976648
Phase
Phase 2
Study Type
Interventional
Last Updated